PubMed Health⌕ Search

Biomedical subjects

P Stern

Publications and source records attributed to P Stern.

7 recordsLinked to original sources
PubMed1979

The effect of prolonged decompaction on the development of the preimplantation mouse embryo.

A rabbit antiserum to a mouse embryonal carcinoma cell line blocks compaction of cleaving mouse embryos. Cell division is not affected up to the 32-cell stage but intracellular junctions fail to develop. Removal of the antibody at this stage permits compaction to occur and a normal blastocyst develops. Prolonged decompaction beyond the 32-cell embryo results in an increasing proportion of malformed blastocysts in which trophectodermal cells predominate and functional inner cell mass (ICM) cells are reduced or absent. The relationship of compaction to the generation of ICM and trophectoderm lineages in the intact embryo is discussed.

Animals↗
PubMed1977

Renal clearances of 14C-inulin and polyfructosan in the rat. Effect of increased ureteral pressure.

Polyfructosan has been used as a substitute for inulin in GFR determinations. However, the validity of this substitution in conditions where renal tubular permeability to other substances, such as mannitol, sucrose and other substances, such as mannitol, sucrose and iothalamate, is increased has not been tested. Experiments were performed on 8 rats to compare the clearances of polyfructosan (CPF) and 14C-inulin (CIN) during hydropenia, 3% BW saline expansion, elevation of one ureteral catheter by 30 cm, and following return of increased ureteral pressure to the control level. No significant difference between CPF and CIN could be detected except in the kidney subjected to increased ureteral pressure. However, the magnitude of this difference--which may relate to the different molecular weights of the two compounds--was so small that we conclude that the use of CPF, as an index of GFR, is no less reliable than CIN under the conditions tested.

Animals↗
PubMed1975

The effect of specific brain phospholipid on the rat's allergic encephalomyelitis.

A new preparation which contains specific brain phospholipids (Gricertine) acts as a histamine liberator in CNS and protects rats from allergic encephalomyelitis. It is supposed that the protective effect of Gricertine on the allergic encephalomyelitis is based on its histamine-liberator properties which can occur during the first days of therapy: this would explain the large decrease of the brain histamine after 3 weeks of treatment. Gricertine is also able to remove clinical symptoms of allergic encephalomyelitis in rats. It is presumed that Gricertine may also be acting independently of that mechanism, in the way that it replaces phospholipids that disappeared in the cases where demyelinisation had taken place.

Animals↗